Kymera Therapeutics KYMR Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's operating lease liabilities?
- Kymera Therapeutics (KYMR) reported operating lease liabilities of $65.59M in Q1 2026.
- How has Kymera Therapeutics's operating lease liabilities changed year-over-year?
- Kymera Therapeutics's operating lease liabilities decreased by 7.9% year-over-year, from $71.18M to $65.59M.
- What is the long-term trend for Kymera Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's operating lease liabilities has grown at a 36.5% compound annual growth rate (CAGR), from $14.13M to $67.03M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.